Cited by 305Cancer Immunotherapy and BiomarkersCancer, Hypoxia, and MetabolismBreast Cancer Treatment Studies

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells

Open access

Samanta, Debangshu, Park, Youngrok, Ni, Xuhao, Li, Huili, Zahnow, Cynthia A., Gabrielson, Edward, Pan, Fan, Semenza, Gregg L.·2018·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1718197115PMC PMC5819443

Open this paper in CoChat — free account Open PDF

Abstract

Significance Cytotoxic chemotherapy is frequently used in patients with triple-negative breast cancer (TNBC). Although patients initially respond to the treatment, the cancer often comes back and kills the patient. Recent studies have demonstrated that cancer cells express genes that protect them from killing by immune cells, but the stimulus that prompts this response is unknown. We show that when TNBC cells are treated with chemotherapy, the surviving cells turn on genes that enable them to escape killing by the immune system. We identify hypoxia-inducible factors (HIFs), which are known to promote metastasis of TNBC, as responsible for this countertherapeutic effect. We show that coadministration of an HIF inhibitor with chemotherapy blocks the ability of surviving TNBC cells to evade the immune system.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.1718197115

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

3 retracted

RETRACTED: Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells
Samanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460
Self-citation
Retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451
Self-citation
Retracted
RETRACTED ARTICLE: HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs
Zhang, H., Wong, C. C. L., Wei, H., Gilkes, D. M., Korangath, P., Chaturvedi, P., Schito, L., Chen, J., Krishnamachary, B., Winnard, P. T., et al. (2012) · Oncogene · doi:10.1038/onc.2011.365 · Cited by 326
Self-citation
Retracted
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Remarkable therapeutic responses to anti-PD1 or antiPDL1 antibodies have occurred in a minority of patients with melanoma, non-small cell lung cancer, and renal carcinoma (22, 23).”
Background

Show all 63 references

Sorted by citations

Items 101–200 of 305

Redox regulation of cancer stem cells: Biology and therapeutic implications
Du, M., Zhang, J., Wicha, M. S., & Luo, M. (2024) · MedComm – Oncology · doi:10.1002/mog2.70005 · Cited by 45
Anticancer effects of anti-CD47 immunotherapy in vivo
Iribarren, K., Buqué, A., Mondragón, L., Xie, W., Lévesque, S., Pol, J. G., Zitvogel, L., Kepp, O., & Kroemer, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1550619 · Cited by 46
Cancer stem cell-derived CHI3L1 activates the MAF/CTLA4 signaling pathway to promote immune escape in triple-negative breast cancer
Ji, S., Yu, H., Zhou, D., Fan, X., Duan, Y., Tan, Y., Lang, M., & Shao, G. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04532-6 · Cited by 50
RETRACTED: Decoding tumor microenvironment: EMT modulation in breast cancer metastasis and therapeutic resistance, and implications of novel immune checkpoint blockers
Yuan, J. X., Li, Y., Zhang, H., Beeraka, N. M., Zhang, D., Wang, Q., Wang, M., Hemanth Vikram, P. R., Sethi, G., & Wang, G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117714 · Cited by 47
Retracted
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
Khan, K. A., de Léon, J. L. P., Benguigui, M., Xu, P., Chow, A., Cruz‐Muñoz, W., Man, S., Shaked, Y., & Kerbel, R. S. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0171-1 · Cited by 42
FTO activates PD-L1 promotes immunosuppression in breast cancer via the m6A/YTHDF3/PDK1 axis under hypoxic conditions
Wang, S., Zhang, X., Chen, Q., Wu, H., Cao, S., Zhao, S., Li, G., Wang, J., Gong, Y., Wang, X., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.026 · Cited by 42
RETRACTED: Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo
Khesht, A. M. S., Karpisheh, V., Gilan, P. S., Melnikova, L. A., Zekiy, A. O., Mohammadi, M., Hojjat‐Farsangi, M., Zolbanin, N. M., Mahmoodpoor, A., Hassannia, H., et al. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.07.034 · Cited by 40
Retracted
Protein-Crowned Micelles for Targeted and Synergistic Tumor-Associated Macrophage Reprogramming to Enhance Cancer Treatment
Sun, J., Liang, X., Cai, M., Yan, L., Chen, Z., Guo, L. M., Li, J., Wang, Y., & Zhou, D. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c00901 · Cited by 41
Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives
Ye, Z.-H., Yu, W., Huang, M., Chen, J., & Lu, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.016 · Cited by 41
Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells
Yang, Y., Zhang, X., Lin, F., Xiong, M., Fan, D., Yuan, X., Yang, L., Song, Y., Zhang, Y., Hao, M., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0723-8 · Cited by 39
The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers
Wang, G., Tai, R., Wu, Y., Yang, S., Wang, J., Yu, X., Lei, L., Shan, Z., & Li, N. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.02.002 · Cited by 38
Trauma-Responsive Scaffold Synchronizing Oncolysis Immunization and Inflammation Alleviation for Post-Operative Suppression of Cancer Metastasis
Li, J., Zhang, P., Zhou, M., Liu, C., Huang, Y., & Li, L. (2022) · ACS Nano · doi:10.1021/acsnano.1c11562 · Cited by 37
Early phago-/endosomal escape of platinum drugs via ROS-responsive micelles for dual cancer chemo/immunotherapy
Shueng, P., Yu, L.-Y., Chiu, H., Chang, H.-C., Chiu, Y., Kuo, T.-Y., Yen, Y.-W., & Lo, C.-L. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121012 · Cited by 37
The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies
Henríquez, J. A., Sleeman, J. P., & Garvalov, B. K. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9930-x · Cited by 37
CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer
Cerbelli, B., Botticelli, A., Pisano, A., Pernazza, A., Campagna, D., Luca, A. D., Ascierto, P. A., Pignataro, M. G., Pelullo, M., Rocca, C. D., et al. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02722-6 · Cited by 36
Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice
Zhang, J., Pan, S., Chen, J., Li, H., Dong, J., Sun, Q., Jin, H., & Han, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.819405 · Cited by 39
Self-citation
The Role of Hypoxia-Inducible Factor Isoforms in Breast Cancer and Perspectives on Their Inhibition in Therapy
Kozal, K., & Krześlak, A. (2022) · Cancers · doi:10.3390/cancers14184518 · Cited by 37
Translation of cancer immunotherapy from the bench to the bedside
Guo, Q., Huang, F., Gonçalves, C., Rincon, S. V. D., & Miller, W. H. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.001 · Cited by 35
Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function
Jin, R., Liu, L., Xing, Y., Meng, T., Ma, L., Pei, J., Cong, Y., Zhang, X., Ren, Z., Wang, X., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0076 · Cited by 35
CircKRT1 drives tumor progression and immune evasion in oral squamous cell carcinoma by sponging miR‐495‐3p to regulate PDL1 expression
Yang, Z., Chen, W., Wang, Y., Qin, M., & Ji, Y. (2021) · Cell Biology International · doi:10.1002/cbin.11581 · Cited by 35
PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer
Zhu, H., Du, C., Yuan, M., Fu, P., He, Q., Yang, B., & Cao, J. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.006 · Cited by 36
The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice
Wu, C., Wu, C.-Y., Lin, C., Liu, Y., Lin, T.-C., Liao, H.-J., & Chang, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113128 · Cited by 34
Enhancing Cancer Chemo‐Immunotherapy: Innovative Approaches for Overcoming Immunosuppression by Functional Nanomaterials
Wang, J., Li, L., & Xu, Z. P. (2023) · Small Methods · doi:10.1002/smtd.202301005 · Cited by 34
Elucidation of Spatial Cooperativity in Chemo‐Immunotherapy by a Sequential Dual‐pH‐Responsive Drug Delivery System
Wang, S., Liu, L., Tian, L., Xu, P., Li, S., Hu, L., Xia, Y., Ding, Y., Wang, J., & Li, S. (2024) · Advanced Materials · doi:10.1002/adma.202403296 · Cited by 34
Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway
Yi, X., Lou, L., Wang, J., Xiong, J., & Zhou, S. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04238-w · Cited by 33
Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment
Lappano, R., Todd, L. A., Stanic, M., Cai, Q., Maggiolini, M., Marincola, F., & Pietrobon, V. (2022) · Cancers · doi:10.3390/cancers14030539 · Cited by 32
DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy
Gilmore, E. S., McCabe, N., Kennedy, R. D., & Parkes, E. E. (2019) · Journal of Oncology · doi:10.1155/2019/4325105 · Cited by 32
Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers
Si, Y., Zhang, Y., Guan, J.-S., Ngo, H. G., Totoro, A., Singh, A. P., Chen, K., Xu, Y., Yang, E. S.-H., Zhou, L., et al. (2021) · Vaccines · doi:10.3390/vaccines9080882 · Cited by 32
Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness
Lan, J., Wei, G., Liu, J., Yang, F., Sun, R., & Lu, H. (2022) · Theranostics · doi:10.7150/thno.70581 · Cited by 31
Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer
Wang, Y., Chen, Y., Ji, D., Huang, Y., Huang, W., Dong, X., Yao, D., & Wang, D. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02727-7 · Cited by 34
Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma
Reiniger, L., Téglási, V., Pipek, O., Rojkó, L., Glasz, T., Vágvölgyi, A., Kovalszky, I., Gyulai, M., Lohinai, Z., Rásó, E., et al. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1598575 · Cited by 31
Identification of a Hypoxia-Related Molecular Classification and Hypoxic Tumor Microenvironment Signature for Predicting the Prognosis of Patients with Triple-Negative Breast Cancer
Sun, X., Luo, H., Chenbo, H., Zhang, Y., & Yan, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700062 · Cited by 31
CD73; a key ectonucleotidase in the development of breast cancer: Recent advances and perspectives
Soleimani, A., Taghizadeh, E., Shahsavari, S., Amini, Y., Rashidpour, H., Azadian, E., Jafari, A., Parizadeh, M. R., Mashayekhi, K., Soukhtanloo, M., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28187 · Cited by 28
Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting
Wu, Z., Zhang, L., Peng, J., Xu, S., Zhou, L., Lin, Y., Wang, Y., Lu, J., Yin, W., & Lu, J. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1583533 · Cited by 29
Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation
Lin, Y., Chiang, S., Chen, C.-Y., Hong, W.-Z., Chen, T.-W., Chen, W. T., Ke, T., Yang, P.-C., Liang, J., Shiau, A., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03416-4 · Cited by 30
Targeting CD47 as a Novel Immunotherapy for Breast Cancer
Chen, C., Wang, R., Chen, X., Hou, Y., & Jiang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924740 · Cited by 30
Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer
Kowash, R. R., & Akbay, E. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130358 · Cited by 29
Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity
Lin, H.-J. L., Liu, Y., Lofland, D., & Lin, J. (2022) · Cancers · doi:10.3390/cancers14020285 · Cited by 28
H2O2/pH Dual-Responsive Biomimetic Nanoenzyme Drugs Delivery System for Enhanced Tumor Photodynamic Therapy
Li, X., Ji, Q., Yan, C., Zhu, Z., Yan, Z., Chen, P., Wang, Y., & Song, L. (2022) · Nanoscale Research Letters · doi:10.1186/s11671-022-03738-9 · Cited by 28
Immunogenic Nanovesicle‐Tandem‐Augmented Chemoimmunotherapy via Efficient Cancer‐Homing Delivery and Optimized Ordinal‐Interval Regime
Sun, M., Shi, W., Wu, Y., He, Z., Sun, J., Cai, S., & Luo, Q. (2022) · Advanced Science · doi:10.1002/advs.202205247 · Cited by 28
Isoliquiritin modulates ferroptosis via NF-κB signaling inhibition and alleviates doxorubicin resistance in breast cancer
Wang, J.-G., Li, Y., Zhang, J., & Luo, C. (2023) · Immunopharmacology and immunotoxicology · doi:10.1080/08923973.2023.2165943 · Cited by 26
Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging
Effer, B. R., Perez, I., Ulloa, D., Mayer, C., Muñoz, F., Bustos, D., Rojas, C., Manterola, C., Vergara-Gómez, L., Dappolonnio, C., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11072086 · Cited by 28
CD47 and CD68 expression in breast cancer is associated with tumor‐infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis
Chen, Y., Klingen, T. A., Aas, H., Wik, E., & Akslen, L. A. (2023) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.309 · Cited by 27
Dual Blockage of Both PD-L1 and CD47 Enhances the Therapeutic Effect of Oxaliplatin and FOLFOX in CT-26 Mice Tumor Model
Alimohammadi, R., Chalbatani, G. M., Alimohammadi, M., Nazari, H. G., Rahimi, A., Mortaz, E., Mossafa, N., Boon, L., Janji, B., & Jalali, S. A. (2022) · Scientific Reports · doi:10.1038/s41598-023-29363-9 · Cited by 26
Hypoxia-Induced Long Noncoding RNA HIF1A- AS2 Regulates Stability of MHC Class I Protein in Head and Neck Cancer
Liao, T., Chen, Y.-H., Li, Z.-Y., Hsiao, A.-C., Huang, Y.-L., Hao, R.-X., Tai, S., Chu, P., Shih, J.-W., Kung, H., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0622 · Cited by 27
Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future
Huang, Y., Gu, Z., Fan, Y., Zhai, G., Zhao, X., Sun, Q., Shi, Y., & Lin, G. (2019) · Purinergic Signalling · doi:10.1007/s11302-018-9641-4 · Cited by 26
Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer
Zhou, Y., Liang, Z., Xia, Y., Li, S., Liang, J., Hu, Z., Tang, C., Zhao, Q., Gong, Q., & Ouyang, Y. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110260 · Cited by 26
Aptamer-Based Strategies to Boost Immunotherapy in TNBC
Agnello, L., d’Argenio, A., Nilo, R., Fedele, M., Camorani, S., & Cerchia, L. (2023) · Cancers · doi:10.3390/cancers15072010 · Cited by 25
Breast cancer cell debris diminishes therapeutic efficacy through heme oxygenase-1-mediated inactivation of M1-like tumor-associated macrophages
Kim, S. H., Saeidi, S., Zhong, X., Gwak, S.-Y., Muna, I. A., Park, S., Kim, S. H., Na, H., Joe, Y., Chung, H., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.08.006 · Cited by 26
Autocrine and Paracrine Purinergic Signaling in the Most Lethal Types of Cancer
Reyna-Jeldes, M., Díaz-Muñoz, M., Madariaga, J. A., Coddou, C., & Vázquez-Cuevas, F. G. (2021) · Purinergic Signalling · doi:10.1007/s11302-021-09785-8 · Cited by 25
Nanoparticle-mediated dual targeting of stromal and immune components to overcome fibrotic and immunosuppressive barriers in hepatocellular carcinoma
Yin, X., Zhao, X., Shen, Y., Xie, W., He, C., Guo, J., Li, Z., Xuan, F., Zeng, S., Zeng, X., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113783 · Cited by 31
A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway
Wurm, M., Schaaf, O., Reutner, K., Ganesan, R., Mostböck, S., Pelster, C., Böttcher, J., Pereira, B. D. A., Taubert, C., Alt, I., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0107 · Cited by 28
Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review)
Ma, X., Wu, J., Wang, B., Liu, C., Liu, L., & Sun, C. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5424 · Cited by 27
The Role and Therapeutic Targeting of CCR5 in Breast Cancer
Hamid, R., Alaziz, M., Mahal, A. S., Ashton, A. W., Halama, N., Jaeger, D., Jiao, X., & Pestell, R. G. (2023) · Cells · doi:10.3390/cells12182237 · Cited by 28
Chemotherapy but Not the Tumor Draining Lymph Nodes Determine the Immunotherapy Response in Secondary Tumors
Zhao, X., Kassaye, B., Wangmo, D., Lou, E., & Subramanian, S. (2020) · iScience · doi:10.1016/j.isci.2020.101056 · Cited by 27
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma
Maakaron, J. E., Asch, A. S., Popplewell, L. L., Collins, G. P., Flinn, I. W., Ghosh, N., Keane, C., Ku, M., Mehta, A., Roschewski, M. J., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013338 · Cited by 24
Innate Immune System in the Context of Radiation Therapy for Cancer
Boopathi, E., Den, R. B., & Thangavel, C. (2023) · Cancers · doi:10.3390/cancers15153972 · Cited by 27
Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas
Zhuang, H., Wang, S., Chen, B., Zhang, Z., Ma, Z., Li, Z., Liu, C., Zhou, Z., Gong, Y., Huang, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.790661 · Cited by 23
Notch1 promotes resistance to cisplatin by up-regulating Ecto-5′-nucleotidase (CD73) in triple-negative breast cancer cells
Qi, Y., Li, M., Li, S., Zeng, D., Xiao, Y., Li, J., Ye, Q., Bremer, E., & Zhang, G. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01487-x · Cited by 23
Novel fully human anti‐CD47 antibodies stimulate phagocytosis and promote elimination of AML cells
Wang, C., Sun, C., Li, M., Xia, B., Wang, Y., Zhang, L., Zhang, Y., Wang, J., Sun, F., Lü, S., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30163 · Cited by 23
A PDA-DTC/Cu–MnO 2 nanoplatform for MR imaging and multi-therapy for triple-negative breast cancer treatment
Hu, X., Lu, Y., Zhao, W., Sun, M., Li, R., Feng, L., Yao, T., Dong, C., & Shi, S. (2021) · Chemical Communications · doi:10.1039/d1cc00987g · Cited by 22
Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers
Si, Y., Chen, K., Ngo, H. G., Guan, J. S., Totoro, A., Zhou, Z. “., Kim, S., Kim, T. H., Zhou, L., & Liu, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010146 · Cited by 22
Antibiotic-Resistant Septicemia in Pediatric Oncology Patients Associated with Post-Therapeutic Neutropenic Fever
Vázquez-López, R., Rojas, O. R., Moreno, A. I., Favila, J. E. U., Peña-Barreto, A., Ortuño, G. L. O., Vaamonde, J. A. A., Velazco, I. A. A., Castro, J. M. F., Solano, S., et al. (2019) · Antibiotics · doi:10.3390/antibiotics8030106 · Cited by 23
Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer
Li, L., Wang, J., Radford, D. C., Kopec̆ek, J., & Yang, J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.011 · Cited by 21
Preclinical PET Imaging of Granzyme B Shows Promotion of Immunological Response Following Combination Paclitaxel and Immune Checkpoint Inhibition in Triple Negative Breast Cancer
Napier, T. S., Hunter, C. L., Song, P. N., Larimer, B. M., & Sorace, A. G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020440 · Cited by 21
Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress
Francesco, E. M. D., Cirillo, F., Vella, V., Belfiore, A., Maggiolini, M., & Lappano, R. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2094762 · Cited by 21
Precisely Amplifying Intracellular Oxidative Storm by Metal–Organic Coordination Polymers to Augment Anticancer Immunity
Li, S., Chen, X., Guan, S., Wang, Z., Cao, W., Luo, G., & Ling, X. (2023) · ACS Nano · doi:10.1021/acsnano.3c04785 · Cited by 21
The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies
Xu, J., Shi, Q., Wang, B., Ji, T., Guo, W., Ren, T., & Tang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1257254 · Cited by 21
Overcoming T Cell Exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano‐Delivery Systems for Enhanced Immunotherapy
Huang, X., & Zhang, W. (2023) · Small Methods · doi:10.1002/smtd.202301326 · Cited by 21
Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
Shi, L., Yang, L., Wu, Z., Xu, W., Song, J. H., & Guan, W. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.07.023 · Cited by 20
A cellular automata model of chemotherapy effects on tumour growth: targeting cancer and immune cells
Pourhasanzade, F., & Sabzpoushan, S. H. (2019) · Mathematical and Computer Modelling of Dynamical Systems · doi:10.1080/13873954.2019.1571515 · Cited by 20
Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells
Sulaiman, A., McGarry, S., Chambers, J., Al‐Kadi, E., Phan, A., Li, L., Mediratta, K., Dimitroulakos, J., Addison, C., Li, X., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165788 · Cited by 20
CpG‐Based Nanovaccines Enhance Ovarian Cancer Immune Response by Gbp2‐Mediated Remodeling of Tumor‐Associated Macrophages
Xiong, J., Huang, J., Xu, H., Wu, Q., Zhao, J., Chen, Y., Fan, G., Guan, H., Xiao, R., He, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202412881 · Cited by 19
HMGB1-containing nucleosome mediates chemotherapy-induced metastasis of human lung cancer
Wang, K., Shan, S., Wang, S., Gu, X., Zhou, X., & Ren, T. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.150 · Cited by 19
Anti‐tumour immune response in GL261 glioblastoma generated by Temozolomide Immune‐Enhancing Metronomic Schedule monitored with MRSI‐based nosological images
Wu, S., Calero‐Pérez, P., Villamañán, L., Arias‐Ramos, N., Pumarola, M. B., Ortega‐Martorell, S., Julià‐Sapé, M., Arús, C., & Candiota, A. P. (2020) · NMR in Biomedicine · doi:10.1002/nbm.4229 · Cited by 19
Immune checkpoint inhibitors for recurrent endometrial cancer
Mutlu, L., Harold, J. A., Tymon‐Rosario, J., & Santin, A. D. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2044311 · Cited by 19
The Effects of CD73 on Gastrointestinal Cancer Progression and Treatment
Sun, P., Zheng, X. W., & Li, X. (2022) · Journal of Oncology · doi:10.1155/2022/4330329 · Cited by 18
Promotion of ICD via Nanotechnology
Qin, Y., Zhang, H., Li, Y., Xie, T., Yan, S., Wang, J., Qu, J., Ouyang, F., Lv, S., Guo, Z., et al. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202300093 · Cited by 18
Integrating single-cell and bulk transcriptomic analyses to develop a cancer-associated fibroblast-derived biomarker for predicting prognosis and therapeutic response in breast cancer
Li, C., Yang, L., Zhang, Y., Hou, Q., Wang, S., Lu, S., Tao, Y., Hu, W., & Zhao, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1307588 · Cited by 19
The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine
Stovgaard, E. S., Asleh, K., Riaz, N., Leung, S. C. Y., Gao, D., Nielsen, L. B., Lænkholm, A., Balslev, E., Jensen, M., Nielsen, D. L., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1924492 · Cited by 17
CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice
Soleimani, A., Mirzavi, F., Nikoofal‐Sahlabadi, S., Nikpoor, A. R., Taghizadeh, B., Barati, M., Soukhtanloo, M., & Jaafari, M. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-14392-7 · Cited by 17
Chemotherapy induces immune checkpoint VISTA expression in tumor cells via HIF-2alpha
Li, N., Yang, S., Ren, Y. X., Tai, R., Liu, H., Wang, Y., Li, J., Wang, F., Xing, J., Zhang, Y., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115492 · Cited by 18
Recent Advancements in CD47 Signal Transduction Pathways Involved in Vascular Diseases
Dou, M., Chen, Y., Hu, J., Ma, D., & Xing, Y. (2020) · BioMed Research International · doi:10.1155/2020/4749135 · Cited by 17
Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
Radosevic‐Robin, N., Selenica, P., Zhu, Y., Won, H. H., Berger, M. F., Ferrando, L., Cocco, E., Privat, M., Ponelle‐Chachuat, F., Abrial, C., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00334-5 · Cited by 17
Cancer immunotherapy by adenosinergic CD39 and CD73 as emerging immune checkpoints
Yin, X., Yang, Y., & Liu, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-04001-0 · Cited by 16
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
Ploeg, E. M., Samplonius, D. F., Xiong, X., Ke, X., Hendriks, M. A. J. M., Britsch, I., van Wijngaarden, A. P., Zhang, H., & Helfrich, W. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006837 · Cited by 16
Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model
Mediratta, K., El‐Sahli, S., Marotel, M., Awan, M. Z., Kirkby, M., Salkini, A., Kurdieh, R., Abdisalam, S., Shrestha, A., Censo, C. D., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366197 · Cited by 17
Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer
Massa, D., Tosi, A., Rosato, A., Guarneri, V., & Dieci, M. V. (2022) · Cancers · doi:10.3390/cancers14194885 · Cited by 17
Tissue Inhibitor of Metalloproteinases-1 Overexpression Mediates Chemoresistance in Triple-Negative Breast Cancer Cells
Agnello, L., d’Argenio, A., Caliendo, A., Nilo, R., Zannetti, A., Fedele, M., Camorani, S., & Cerchia, L. (2023) · Cells · doi:10.3390/cells12131809 · Cited by 15
Co-assembly of polymeric conjugates sensitizes neoadjuvant chemotherapy of triple-negative breast cancer with reduced systemic toxicity
Ren, L. F., Zhang, Q., Wang, W., Chen, X., Li, Z., Gong, Q., Gu, Z., & Luo, K. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.12.026 · Cited by 15
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research
Moniot, A., Schneider, C., Chardin, L., Yaniz‐Galende, E., Genestie, C., Etiennot, M., Henry, A., Drelon, C., Formal, A. L., Langlois, B., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02073-0 · Cited by 16
SNAI1-dependent upregulation of CD73 increases extracellular adenosine release to mediate immune suppression in TNBC
Hasmim, M., Xiao, M., Moer, K. V., Kumar, A., Oniga, A., Mittelbronn, M. G. A., Duhem, C., Chammout, A., Berchem, G., Thiery, J. P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982821 · Cited by 17
The role of hypoxia-inducible factors in breast cancer stem cell specification
Fath, M. K., Garousi, S., Mottahedi, M., Ghasemzadeh, N., Salmani, K., Olfati, F., Saeed, M. B., Sotoudeh, S., & Barati, G. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154349 · Cited by 15
Effects of Combinatorial Ubiquitinated Protein-Based Nanovaccine and STING Agonist in Mice With Drug-Resistant and Metastatic Breast Cancer
Huang, F., Pan, N., Wei, Y., Zhao, J., Aldarouish, M., Wang, X., Sun, X., Wen, Z., Chen, Y., & Wang, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.707298 · Cited by 15
Tumor-resident adenosine-producing mesenchymal stem cells as a potential target for cancer treatment
Arab, S., Alizadeh, A., & Asgharzade, S. (2021) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00674-9 · Cited by 14
Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
Kondo, S., Iwasa, S., Koyama, T., Fujita, T., Sugibayashi, K., Murayama, K., & Yamamoto, N. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02242-5 · Cited by 14
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial
Wainberg, Z. A., Manji, G. A., Bahary, N., Ulahannan, S. V., Pant, S., Spigel, D. R., Uboha, N. V., Oberstein, P. E., Saeed, A., Beagle, B. R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04283-z · Cited by 13
Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation
Mendoza, M. S., Romero‐Garcia, S., Lemini, C., & Prado-Garcı́a, H. (2021) · Journal of Immunology Research · doi:10.1155/2021/6668573 · Cited by 13
Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
Xiao, A., & Akilov, O. E. (2022) · Cells · doi:10.3390/cells11223591 · Cited by 13
Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?
Karachaliou, N., Fernández-Bruno, M., & Rosell, R. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.07.02 · Cited by 13

Authors: Samanta, D., Park, Y., Ni, X., Li, H., Zahnow, C. A., Gabrielson, E., Pan, F., & Semenza, G. L.
Affiliations: Johns Hopkins University (US)
Corresponding author: Semenza, Gregg L.
ORCID: Ni, Xuhao
Li, Huili
Zahnow, Cynthia A.
Gabrielson, Edward
Pan, Fan
Semenza, Gregg L.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2018-01-24
Volume: 115
Issue: 6
Pages: E1239-E1248
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1718197115
PMC: PMC5819443
OpenAlex: W2785041354
Cited by: 302
References: 63
Citations by year: 2026: 13 · 2025: 19 · 2024: 35 · 2023: 47 · 2022: 53 · 2021: 45 · 2020: 43 · 2019: 28 · 2018: 17
FWCI: 12.50
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.pnas.org/site/aboutpnas/licenses.xhtml (vor, 181 d)
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Emerson Collective Cancer Research Fund (n/a)
American Cancer Society (RP-16-239-06-COUN)
Cindy Rosencrans Fund for Triple Negative Breast Cancer (n/a)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: triple-negative breast cancer, chemoresistance, immune evasion, CD47, CD73, PD-L1, hypoxia-inducible factor, HIF inhibitors, tumor immune evasion, tumor cell survival
MeSH terms: Animals, Antineoplastic Agents, Female, Humans, Mice, Inbred BALB C, Mice, Inbred C57BL, T-Lymphocytes, Tumor Cells, Cultured, 5'-Nucleotidase, Gene Expression Regulation, Neoplastic, Apoptosis, Tumor Escape, Xenograft Model Antitumor Assays, Mice, Hypoxia-Inducible Factor 1, CD47 Antigen, GPI-Linked Proteins, B7-H1 Antigen, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks